Thigh-length compression stockings and DVT after stroke
Deep vein thrombosis (DVT) and pulmonary embolism (PE) are key complications after stroke that can lead to substantial morbidity and mortality. Rates of venous thromboembolism (VTE) were high in the past but have fallen, 1 refl ecting increased use of early rehydration, mobilisation, and aspirin. 2, 3 An additional intervention is the use of graduated compression stockings (GCS), the effi cacy of which, although shown for surgery, 4 is unproven in stroke. 1, 5 In The Lancet today, Martin Dennis and colleagues 6 present the results of the CLOTS 1 trial, the fi rst large assessment of the safety and effi cacy of thigh-length GCS in patients with recent stroke. The CLOTS 1 trial is vitally important for stroke care. 2518 patients were recruited from 64 centres in Australia, Italy, and the UK (in the latter case, benefi tting from the UK Stroke Research Network) within 3 days of admission after stroke, and were representative of patients entering stroke services. The primary outcome was symptomatic or asymptomatic DVT detected on compression Doppler ultrasound, or symptomatic DVT, in the popliteal or femoral veins occurring within 30 days of randomisation. The trial found that GCS did not reduce DVT, compared with no GCS (absolute reduction 0·5%, 95% CI -1·9% to 2·9%, number needed to treat 200). GCS did not aff ect key secondary outcomes, including components of the primary outcome, as well as PE, VTE, and death. Importantly, GCS did not seem to be benefi cial in prespecifi ed subgroups: patients treated early, those with leg weakness, and those not given concomitant anticoagulation. Equally importantly, the use of GCS was associated with a fourfold increase in skin ulcers and necrosis, and a nonsignifi cant increase in lower-limb ischaemia. These results are supported by an earlier observational study that also found no benefi t with GCS. 7 These fi ndings suggest that GCS do not work after stroke, although they do work after surgery. 4 This might refl ect diff erences in the age of patients, duration of immobility, and comorbidities. Alternatively, CLOTS 1 could have obtained the wrong result. First, the trial might have been too small since it was only powered to detect a 4% absolute reduction in the primary outcome. However, the logistics and health economics of administering GCS to reduce DVT by, say, 2% are probably not worthwhile-for example, 24 stroke patients would need about 0·3 of a nurse per day just to measure and fi t GCS, with an additional cost per patient of about £20 for the stockings (assuming three pairs per patient). Second, the rate of proximal DVT (the type most likely to lead to PE) was lower than expected (10% vs 12%), which will have reduced the power of the study. Third, the trial was necessarily unblinded; however, the detection of DVT was made blinded to therapy by removing GCS with suffi cient time before ultrasound to allow skin indentations to disappear. Lack of treatment blinding could mean that investigators managed patients diff erently; the 0·8% excess use of anticoagulation in patients randomised to avoid GCS might indicate such a bias, although this is unlikely to have infl uenced the overall fi ndings. Fourth, although centres were trained in the sizing and fi tting of GCS, it is likely that both trial and clinical practice can result in the incorrect use of GCS; this practice would be ineff ective or even hazardous. Last, compliance is important 7 and the CLOTS 1 investigators report that this was only 79% in the fi rst 14 days, and 73% up to 30 days.
What then should be used for VTE prophylaxis after stroke? CLOTS 2 is a comparison of thigh-length versus below-knee GCS, but this trial will now close early in view of the CLOTS 1 results. Intermittent pneumatic compression has also been studied 5, 8 and CLOTS 3 is assessing this approach. Subcutaneous low-tomedium dose heparin is eff ective in reduction of VTE but unfortunately the reduction in PE, the primary Comment target for prevention, is matched by a similar increase in symptomatic intracerebral haemorrhage and the absolute rates of both events are similar. [9] [10] [11] Worse still, the risk factors for VTE and symptomatic intracerebral haemorrhage are similar (eg, age and severity) so it is not possible to identify patients who are at high risk of VTE but not bleeding. Thus, prophylactic heparin cannot be recommended routinely after ischaemic stroke. However, low-molecular-weight heparin (which is more eff ective than unfractionated heparin 12 and only needs to be given once daily) should probably be used in patients who are at very high risk of VTE, such as those with previous VTE, known thrombophilia, or morbid obesity.
In summary, GCS do not reduce DVT or overall VTE in patients with recent stroke; indeed, they damage the skin and might promote limb ischaemia. GCS should not be used after stroke and current guidelines 13, 14 will need to be amended. No specifi c prophylaxis appears to be necessary, although early rehydration, mobilisation, and aspirin are key cornerstones of good stroke care. Prophylactic heparin should be used only in patients at very high risk of VTE; routine use, as currently recommended in guidelines, 13, 14 is not appropriate because of the increased risk of intracerebral haemorrhage. The role of GCS now needs to be assessed urgently in other settings where they might also lack effi cacy, including in general medical patients. 
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Understanding childhood sexual abuse in Africa
In The Lancet today, Avid Reza and colleagues present survey data on sexual violence in girls in Swaziland.
1 In this survey, one of the few nationally representative samples from Africa, a third of girls and women aged 13-24 years reported some form of sexual violence before age 18 years. Most perpetrators were men from their own household or in the immediate neighbourhood. These data should dispel perceptions that Africa has somehow escaped this global tragedy.
Sexual abuse of girls is widely reported by Africa's popular press, often in the context of school. 2 However, few studies have examined the frequency and nature of sexual violence in a representative manner from national or subnational populations. Where studies have been done, methodology and defi nitional issues have limited comparability across sites. Nonetheless, the patterns from population and anecdotal studies in east Africa and elsewhere have found widespread sexual abuse of girls in patterns consistent with those reported from Swaziland. [3] [4] [5] [6] Reza and colleagues sought information about multiple types of sexual violence against girls, and their work can form a benchmark for future studies. Results from sexual-abuse surveys are thought to widely underestimate prevalence, because the trauma surrounding events might aff ect recall and the
